孟鲁司特钠联合舒利迭治疗尘肺合并哮喘的疗效观察

发布时间：2018-05-15 02:43

本文选题：舒利迭 + 孟鲁司特钠　；参考：《中国工业医学杂志》2014年01期

【摘要】：将60例尘肺患者随机分为治疗组和对照组,每组30例,治疗组给予舒利迭吸入及口服孟鲁司特钠,对照组单纯吸入舒利迭,两组均治疗6个月并随访6个月。结果显示,治疗组临床疗效优于对照组;治疗组治疗前、后肺功能各项指标差异有统计学意义(P0.05);治疗组治疗后嗜酸性粒细胞(EOS)减少、免疫球蛋白(IgE)降低,与治疗前比较差异有统计学意义(P0.05)。提示舒利迭联合孟鲁司特钠可提高尘肺稳定期合并哮喘患者的临床疗效。
[Abstract]:60 patients with pneumoconiosis were randomly divided into treatment group (n = 30) and control group (n = 30). The results showed that the clinical curative effect of the treatment group was better than that of the control group, the lung function indexes of the treatment group were significantly different before and after treatment (P 0.05), the eosinophilic granulocyte (EOS) decreased and the immunoglobulin IgE (IgE) decreased after treatment in the treatment group. The difference was statistically significant compared with that before treatment (P 0.05). The results suggest that sultidide combined with montelukast sodium can improve the clinical efficacy of pneumoconiosis combined with asthma.
【作者单位】：天津市职业病防治院;
【分类号】：R135.2;R562.25

【参考文献】